Viktoria Bergqvist
Lund, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis - report of two filgotinib-treated cases and literature review.
Journal: Acta oncologica (Stockholm, Sweden)
Published: July 03, 2025
Endoscopic scoring of immune-mediated colitis disease activity.
Journal: Gastrointestinal endoscopy
Published: October 03, 2024
A new Simple Endoscopic Score for Ulcerative Colitis - the SES-UC.
Journal: Frontiers in gastroenterology (Lausanne, Switzerland)
Published: July 22, 2024
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.
Journal: Digestive diseases and sciences
Published: August 11, 2023
Letter: to switch or not to switch, that is the question-author's reply.
Journal: Alimentary pharmacology & therapeutics
Published: August 08, 2022
Editorial: intravenous to subcutaneous vedolizumab-switch without glitch! Authors' reply.
Journal: Alimentary pharmacology & therapeutics
Published: June 24, 2022
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
Journal: Alimentary pharmacology & therapeutics
Published: February 24, 2022
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease.
Journal: Therapeutic advances in gastroenterology
Published: June 15, 2018
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
Journal: Cancer immunology, immunotherapy : CII
Published: October 16, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026